SG11202110033UA - Pharmaceutical composition for treating amyotrophic lateral sclerosis - Google Patents
Pharmaceutical composition for treating amyotrophic lateral sclerosisInfo
- Publication number
- SG11202110033UA SG11202110033UA SG11202110033UA SG11202110033UA SG11202110033UA SG 11202110033U A SG11202110033U A SG 11202110033UA SG 11202110033U A SG11202110033U A SG 11202110033UA SG 11202110033U A SG11202110033U A SG 11202110033UA SG 11202110033U A SG11202110033U A SG 11202110033UA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- lateral sclerosis
- amyotrophic lateral
- treating amyotrophic
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019046572 | 2019-03-14 | ||
| PCT/JP2020/012566 WO2020184729A1 (en) | 2019-03-14 | 2020-03-13 | Pharmaceutical composition for treating amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110033UA true SG11202110033UA (en) | 2021-10-28 |
Family
ID=72426891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110033UA SG11202110033UA (en) | 2019-03-14 | 2020-03-13 | Pharmaceutical composition for treating amyotrophic lateral sclerosis |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220133805A1 (en) |
| EP (1) | EP3939660A4 (en) |
| JP (1) | JP7541699B2 (en) |
| KR (1) | KR20210138655A (en) |
| CN (1) | CN113557025A (en) |
| AU (1) | AU2020236160B2 (en) |
| CA (1) | CA3133038A1 (en) |
| IL (1) | IL286321A (en) |
| SG (1) | SG11202110033UA (en) |
| WO (1) | WO2020184729A1 (en) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9682319B2 (en) | 2002-07-31 | 2017-06-20 | Sony Interactive Entertainment Inc. | Combiner method for altering game gearing |
| DK2194121T3 (en) * | 2007-09-11 | 2016-12-12 | Univ Sapporo Medical | CELL GROWTH PROCESS AND PHARMACEUTICAL COMPOSITION FOR tissue repair and regeneration |
| KR102811933B1 (en) | 2011-11-30 | 2025-05-23 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | Mesenchymal stromal cells and uses related thereto |
| BR112015001435B1 (en) | 2012-08-06 | 2022-01-18 | Brainstorm Cell Therapeutics Ltd | METHODS FOR GENERATION OF CELLS THAT SECRET BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF), GLIA-DERIVED NEUROTROPHIC FACTOR (GDNF), HEPATOCYTE GROWTH FACTOR (HGF) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN WHICH THESE CELLS DO NOT SECRET FACTOR NERVE GROWTH (NGF) |
| JP7101367B2 (en) * | 2016-04-28 | 2022-07-15 | 北海道公立大学法人 札幌医科大学 | Synaptogen |
| EP3484490A2 (en) * | 2016-07-18 | 2019-05-22 | Brainstorm Cell Therapeutics Ltd. | Methods for treating amyotrophic lateral sclerosis (als) |
| EP3501525A4 (en) | 2016-08-18 | 2020-04-08 | Sapporo Medical University | LIFETIME EXTENSION |
| EP3534921A4 (en) * | 2016-11-03 | 2020-06-03 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
| JP6942565B2 (en) | 2017-08-30 | 2021-09-29 | 京セラ株式会社 | Power generator, control device and control program |
-
2020
- 2020-03-13 JP JP2021505167A patent/JP7541699B2/en active Active
- 2020-03-13 SG SG11202110033UA patent/SG11202110033UA/en unknown
- 2020-03-13 CA CA3133038A patent/CA3133038A1/en active Pending
- 2020-03-13 WO PCT/JP2020/012566 patent/WO2020184729A1/en active Application Filing
- 2020-03-13 CN CN202080020080.0A patent/CN113557025A/en active Pending
- 2020-03-13 US US17/438,833 patent/US20220133805A1/en active Pending
- 2020-03-13 KR KR1020217032458A patent/KR20210138655A/en active Pending
- 2020-03-13 AU AU2020236160A patent/AU2020236160B2/en active Active
- 2020-03-13 EP EP20771155.7A patent/EP3939660A4/en active Pending
-
2021
- 2021-09-12 IL IL286321A patent/IL286321A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3939660A4 (en) | 2022-12-28 |
| KR20210138655A (en) | 2021-11-19 |
| JPWO2020184729A1 (en) | 2020-09-17 |
| CN113557025A (en) | 2021-10-26 |
| IL286321A (en) | 2021-10-31 |
| WO2020184729A1 (en) | 2020-09-17 |
| AU2020236160B2 (en) | 2025-07-24 |
| AU2020236160A1 (en) | 2021-09-16 |
| US20220133805A1 (en) | 2022-05-05 |
| EP3939660A1 (en) | 2022-01-19 |
| JP7541699B2 (en) | 2024-08-29 |
| CA3133038A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016351919B2 (en) | Compounds for treating amyotrophic lateral sclerosis | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| IL289213A (en) | Pharmaceutical composition for treating tumor | |
| SG11202103415WA (en) | Compositions and methods for treating and preventing amyotrophic lateral sclerosis | |
| ZA201803320B (en) | Pharmaceutical compositions for treating pain | |
| SG11202107562VA (en) | Composition for preventing, alleviating or treating neurodegenerative diseases, comprising pediococcus inopinatus | |
| ZA202102940B (en) | Pharmaceutical composition for treating aplastic anemia | |
| KR102316727B9 (en) | Pharmaceutical composition for preventing or treating atopic diseases | |
| PT3508202T (en) | Therapeutic agent for amyotrophic lateral sclerosis and composition for treatment | |
| EP4074316A4 (en) | Pharmaceutical composition for preventing or treating cancer | |
| SG11202110315SA (en) | Pharmaceutical composition | |
| SI3908321T1 (en) | Pharmaceutical composition | |
| PL3773641T3 (en) | Topical pharmaceutical compositions for treating skin conditions | |
| IL261360A (en) | Composition and method for treating amyotrophic lateral sclerosis | |
| IL286321A (en) | Pharmaceutical composition for treating amyotrophic lateral sclerosis | |
| IL260331A (en) | Composition and method for treating amyotrophic lateral sclerosis | |
| IL287046A (en) | Solid pharmaceutical compositions for treating hcv | |
| IL285728A (en) | Pharmaceutical composition | |
| SG11202105231UA (en) | Pharmaceutical composition for treating wounds | |
| PL4027974T3 (en) | Pharmaceutical composition containing p-boronophenylalanine | |
| EP3811973A4 (en) | Composition for preventing or treating neurodegenerative disease | |
| HK40060693A (en) | Compositions and methods for treating and preventing amyotrophic lateral sclerosis | |
| EP3993801A4 (en) | Pharmaceutical composition for treating insomnia | |
| HK40115855A (en) | Therapeutic agent and therapeutic composition for amyotrophic lateral sclerosis | |
| GB201912686D0 (en) | Pharmaceutical composition |